Home The Word Brain	My Amedeo FAQ Privacy About
	Chinese Coaching Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.

Leukemia

Free Subscription 08.12.2025 1 Am J Clin Oncol 1 Am J Hematol 2 Ann Hematol 4 Blood 2 BMC Cancer 4 Bone Marrow Transplant 1 Cancer Chemother Pharmacol 1 Exp Hematol 1 J Biol Chem 6 Leuk Lymphoma 1 Leukemia 3 N Engl J Med

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Clin Oncol

1. GEORGE B, Pandey M, Herstein J, Maiti A, et al
   Optimizing Natural Killer Cellular Therapy in Acute Myeloid Leukemia.
   Am J Clin Oncol. 2025 Dec 3. doi: 10.1097/COC.0000000000001262.
   PubMed         Abstract available
   
   

   
   Am J Hematol

2. KURITA N, Maruo K, Kimura F, Kuwatsuka Y, et al
   Platelet Recovery and Its Impact on Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation: A Japanese Nationwide Retrospective Study.
   Am J Hematol. 2026;101:193-197.
   PubMed         Abstract available
   
   

   
   Ann Hematol

3. BARTOLUCCI P, Gigli F, Tabanelli V, Valeriano A, et al
   BCR::ABL1-positive chronic myeloid leukaemia in a scenario of a remote diagnosis of JAK2-V617F-mutated polycythemia vera: a single patient experience with imatinib and ruxolitinib combination therapy.
   Ann Hematol. 2025;104:6065-6069.
   PubMed         Abstract available
   
   
4. HUANG W, Zhang F, Xie J, Wu C, et al
   A novel fusion gene of NUP98::CYP2F2P in myeloid neoplasm.
   Ann Hematol. 2025;104:6071-6074.
   PubMed         Abstract available
   
   

   
   Blood

5. 
   Marchand T, Lamy T, Loughran TP Jr. A modern view of LGL leukemia. Blood. 2024;144(18):1910-1923.
   Blood. 2025;146:2844.
   PubMed        
   
   
6. AZEVEDO RS, Jabbour E, Kantarjian HM, Lavu S, et al
   Impact of TP53 mutations and their variant allele frequency in adults with newly diagnosed acute lymphoblastic leukemia.
   Blood. 2025 Nov 10:blood.2025030498. doi: 10.1182/blood.2025030498.
   PubMed         Abstract available
   
   
7. SHANMUGANATHAN N, Yeung DT, Wadham C, Fernandes A, et al
   Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations.
   Blood. 2025;146:2821-2832.
   PubMed         Abstract available
   
   
8. PAN J, Zhao L, Zhang Y, Seery S, et al
   Donor-derived CD7 CAR T cells for pediatric and adult relapsed/refractory T-ALL/LBL: a phase 2 trial.
   Blood. 2025;146:2745-2757.
   PubMed         Abstract available
   
   

   
   BMC Cancer

9. FALAHAN SN, Mohammadi R, Ayubi E, Yousofvand V, et al
   Comparing the effects of pictorial and Teach-Back education methods on self-efficacy and quality of life in patients with leukemia: a randomized controlled trial.
   BMC Cancer. 2025;25:1843.
   PubMed         Abstract available
   
   
10. MESILHY R, Khan MN, Syed A, Hourani R, et al
    Comparative survival outcomes between therapy-related and de novo acute lymphoblastic leukemia in adults: a systematic review and meta-analysis.
    BMC Cancer. 2025 Nov 29. doi: 10.1186/s12885-025-15366.
    PubMed        
    
    

    
    Bone Marrow Transplant

11. JULLIEN M, Brissot E, Daguindau E, Loschi M, et al
    Thiotepa-busulfan-fludarabine compared to clofarabine-based conditioning for haploidentical transplant with posttransplant cyclophosphamide in patients with myeloid malignancies: a retrospective study from the SFGM-TC.
    Bone Marrow Transplant. 2025;60:1592-1600.
    PubMed         Abstract available
    
    
12. DI MAJO BE, Abouqateb M, Galimard JE, Dalissier A, et al
    Single unrelated umbilical cord blood versus unmanipulated haploidentical HCT using PTCy in pediatric AML: a retrospective study on behalf of the EBMT PDWP and CTIWP.
    Bone Marrow Transplant. 2025;60:1635-1641.
    PubMed         Abstract available
    
    
13. VILLALBA M, Ferhat AT, Gedde-Dahl T, Socie G, et al
    Impact of donor selection in adverse-risk AML undergoing hematopoietic cell transplantation: A study from the EBMT Acute Leukemia Working Party.
    Bone Marrow Transplant. 2025 Nov 29. doi: 10.1038/s41409-025-02751.
    PubMed         Abstract available
    
    
14. BERTAINA A, Maffeis M, Lucchini G, Galimard JE, et al
    Interplay between acute graft-versus-host disease and graft-versus-leukemia effect in pediatric acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: implications for relapse incidence and survival - an EBMT PD
    Bone Marrow Transplant. 2025 Dec 1. doi: 10.1038/s41409-025-02748.
    PubMed         Abstract available
    
    

    
    Cancer Chemother Pharmacol

15. BRILLAC C, Semiond D, Oprea C, Baruchel A, et al
    Selection of isatuximab dosing regimen in pediatric patients with leukemia using population pharmacokinetics.
    Cancer Chemother Pharmacol. 2025;95:116.
    PubMed         Abstract available
    
    

    
    Exp Hematol

16. ROY R, Paul T, Das PK, Sinha S, et al
    ERK-mTOR crosstalk suppresses Autophagy and upregulates proteasomal degradation pathway to confer Chronic Myeloid Leukemia cells resistant to Imatinib.
    Exp Hematol. 2025 Nov 28:105330. doi: 10.1016/j.exphem.2025.105330.
    PubMed         Abstract available
    
    

    
    J Biol Chem

17. YANG WS, Ghanem NZ, Scahill SD, Caliva MJ, et al
    Phosphorylation at S1288 of Leukemia Associated RhoGEF (LARG/ARHGEF12) induces plasma membrane localization and promotes binding and activation of RhoA.
    J Biol Chem. 2025 Dec 1:110996. doi: 10.1016/j.jbc.2025.110996.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

18. KUEK V, Kotecha RS, Cheung LC
    Beyond bone: the emerging role of osteoclasts in immune regulation, leukemia development and following myeloablative therapy.
    Leuk Lymphoma. 2025 Dec 4:1-15. doi: 10.1080/10428194.2025.2595220.
    PubMed         Abstract available
    
    
19. PONNUSAMY U, Perumal V
    Comprehensive review on learning models of leukemia detection based on morphological information.
    Leuk Lymphoma. 2025 Dec 4:1-27. doi: 10.1080/10428194.2025.2583449.
    PubMed         Abstract available
    
    
20. ANGELUCCI E, Deconinck E, Benoit TM, Braitsch K, et al
    Real-world study of tagraxofusp monotherapy in relapsed or refractory blastic plasmacytoid dendritic cell neoplasm.
    Leuk Lymphoma. 2025;66:2489-2497.
    PubMed         Abstract available
    
    
21. HAAKSMA LH, Cloos J, Leeuw DC
    Flow cytometric and molecular MRD in AML: current methods, clinical applications and challenges.
    Leuk Lymphoma. 2025;66:2357-2368.
    PubMed         Abstract available
    
    
22. ZHANG L, Yi M, Chen X, Guo Y, et al
    Measurable residual disease dynamics holding prognostic significance in pediatric patients with RUNX1::RUNX1T1-positive AML: results from AML-CAMS serial trials.
    Leuk Lymphoma. 2025;66:2457-2465.
    PubMed         Abstract available
    
    
23. URRUTIA S, Jen WY, Sasaki K, Wiernik PH, et al
    Mortality and relapse dynamics in AML after three years of complete remission.
    Leuk Lymphoma. 2025;66:2498-2503.
    PubMed         Abstract available
    
    

    
    Leukemia

24. TEDESCHI A, Frustaci AM, Menna P, Minotti G, et al
    Correction: Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.
    Leukemia. 2025 Dec 2. doi: 10.1038/s41375-025-02824.
    PubMed        
    
    

    
    N Engl J Med

25. MUNIR T, Cairns DA, Hillmen P
    Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia. Reply.
    N Engl J Med. 2025;393:2280.
    PubMed        
    
    
26. WANG Y, Zhu Z, Liang Y
    Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.
    N Engl J Med. 2025;393:2279-2280.
    PubMed        
    
    
27. FLEISCHMAN RA
    Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.
    N Engl J Med. 2025;393:2279.
    PubMed        
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.